Datapoint: Regeneron’s Evkeeza Scores First-in-Class Approval for Ultra-Rare Heart Disease

The FDA on Feb. 11 approved Regeneron Pharmaceuticals, Inc.’s Evkeeza as an adjunct treatment to other low-density lipoprotein lowering therapies in patients 12 and older with homozygous familial hypercholesterolemia (HoFH), an ultra-rare genetic form of high cholesterol. This is Regeneron’s first cholesterol win since its 2015 launch of Praluent. Praluent (a joint venture with Sanofi) is not approved to treat HoFH, unlike PCSK9 rival Repatha, an Amgen stalwart. For the treatment of HoFH, Repatha holds preferred formulary placement for 2% of all covered lives, growing to 51% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 2/22/21

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 15

Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today